EMA Authorised: NovoRapid (insulin aspart) — Novo Nordisk A/S

View source ↗

Summary

EMA authorised NovoRapid (insulin aspart) for the treatment of diabetes mellitus; decision date 28 May 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• NovoRapid (insulin aspart)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus. MAH: Novo Nordisk A/S. Decision date: 28/05/2025